Working With Patients To Use AI Against Rare Diseases
An Interview With Tim Guilliams, CEO of Healx
Tim Guilliams, CEO of Healx, talks about the company’s mission of creating from existing drugs new options for rare disease patients. The company is using artificial intelligence to find combination treatments against rare conditions, while working closely with patient groups as key partners in the development process. The goal: faster development timelines and cheaper therapies for patients.
You may also be interested in...
The Scrip 100 universe gathers FY2021 financial performance data and compares the activities of the top 100 biopharma businesses, ranked by pharma sales.
A selection of articles you might have missed from April 2022, including exclusive interviews, an in depth look at the impact of COVID-19 on clinical trial trends, and the latest Rising Leaders series.
Rising Leader Yolanda Tibbe, Novartis’s head of new commercial partnerships in Germany, talks about transformation at the Swiss big pharma and how to put ‘patients as customers’ thinking into action.